FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306829859> ?p ?o ?g. }

• W4306829859 endingPage "1295" @default.
• W4306829859 startingPage "1285" @default.
• W4306829859 abstract "To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM). The primary objective was OS, and secondary objectives included PFS, response rate, and treatment adverse events (AEs) including delayed CNS toxicities.NRG Oncology/RTOG1205 is a prospective, phase II, randomized trial of re-RT and BEV versus BEV alone. Stratification factors included age, resection, and Karnofsky performance status (KPS). Patients with recurrent GBM with imaging evidence of tumor progression ≥ 6 months from completion of prior chemo-RT were eligible. Patients were randomly assigned 1:1 to re-RT, 35 Gy in 10 fractions, with concurrent BEV IV 10 mg/kg once in every 2 weeks or BEV alone until progression.From December 2012 to April 2016, 182 patients were randomly assigned, of whom 170 were eligible. Patient characteristics were well balanced between arms. The median follow-up for censored patients was 12.8 months. There was no improvement in OS for BEV + RT, hazard ratio, 0.98; 80% CI, 0.79 to 1.23; P = .46; the median survival time was 10.1 versus 9.7 months for BEV + RT versus BEV alone. The median PFS for BEV + RT was 7.1 versus 3.8 months for BEV, hazard ratio, 0.73; 95% CI, 0.53 to 1.0; P = .05. The 6-month PFS rate improved from 29.1% (95% CI, 19.1 to 39.1) for BEV to 54.3% (95% CI, 43.5 to 65.1) for BEV + RT, P = .001. Treatment was well tolerated. There were a 5% rate of acute grade 3+ treatment-related AEs and no delayed high-grade AEs. Most patients died of recurrent GBM.To our knowledge, NRG Oncology/RTOG1205 is the first prospective, randomized multi-institutional study to evaluate the safety and efficacy of re-RT in recurrent GBM using modern RT techniques. Overall, re-RT was shown to be safe and well tolerated. BEV + RT demonstrated a clinically meaningful improvement in PFS, specifically the 6-month PFS rate but no difference in OS." @default.
• W4306829859 created "2022-10-20" @default.
• W4306829859 creator A5001497458 @default.
• W4306829859 creator A5002485541 @default.
• W4306829859 creator A5022827643 @default.
• W4306829859 creator A5025967381 @default.
• W4306829859 creator A5027150108 @default.
• W4306829859 creator A5027798049 @default.
• W4306829859 creator A5029952866 @default.
• W4306829859 creator A5031842995 @default.
• W4306829859 creator A5036433314 @default.
• W4306829859 creator A5042756485 @default.
• W4306829859 creator A5045668242 @default.
• W4306829859 creator A5049013672 @default.
• W4306829859 creator A5049018134 @default.
• W4306829859 creator A5066404810 @default.
• W4306829859 creator A5074754509 @default.
• W4306829859 creator A5075996643 @default.
• W4306829859 creator A5087581923 @default.
• W4306829859 date "2023-02-20" @default.
• W4306829859 modified "2023-10-09" @default.
• W4306829859 title "NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma" @default.
• W4306829859 cites W1888656932 @default.
• W4306829859 cites W1933614403 @default.
• W4306829859 cites W1959628099 @default.
• W4306829859 cites W1969965083 @default.
• W4306829859 cites W1981424747 @default.
• W4306829859 cites W1982236564 @default.
• W4306829859 cites W1990995664 @default.
• W4306829859 cites W1995676834 @default.
• W4306829859 cites W2006233465 @default.
• W4306829859 cites W2012063336 @default.
• W4306829859 cites W2012562754 @default.
• W4306829859 cites W2028350902 @default.
• W4306829859 cites W2036560693 @default.
• W4306829859 cites W2055009621 @default.
• W4306829859 cites W2060551076 @default.
• W4306829859 cites W2073649720 @default.
• W4306829859 cites W2075927627 @default.
• W4306829859 cites W2076649680 @default.
• W4306829859 cites W2077964273 @default.
• W4306829859 cites W2093783077 @default.
• W4306829859 cites W2096287682 @default.
• W4306829859 cites W2104352635 @default.
• W4306829859 cites W2105713954 @default.
• W4306829859 cites W2123610802 @default.
• W4306829859 cites W2124268471 @default.
• W4306829859 cites W2127745545 @default.
• W4306829859 cites W2132697290 @default.
• W4306829859 cites W2133616597 @default.
• W4306829859 cites W2136963436 @default.
• W4306829859 cites W2137686302 @default.
• W4306829859 cites W2139984188 @default.
• W4306829859 cites W2147628739 @default.
• W4306829859 cites W2149721689 @default.
• W4306829859 cites W2153894189 @default.
• W4306829859 cites W2157500906 @default.
• W4306829859 cites W2158106887 @default.
• W4306829859 cites W2159538968 @default.
• W4306829859 cites W2162643152 @default.
• W4306829859 cites W2165772224 @default.
• W4306829859 cites W2170367762 @default.
• W4306829859 cites W2324016316 @default.
• W4306829859 cites W2334497865 @default.
• W4306829859 cites W2436534309 @default.
• W4306829859 cites W2463645998 @default.
• W4306829859 cites W2516829090 @default.
• W4306829859 cites W2604251942 @default.
• W4306829859 cites W2753713884 @default.
• W4306829859 cites W2768388636 @default.
• W4306829859 cites W2791378348 @default.
• W4306829859 cites W2794618224 @default.
• W4306829859 cites W2901969541 @default.
• W4306829859 cites W2902545660 @default.
• W4306829859 cites W2904710333 @default.
• W4306829859 cites W2952870574 @default.
• W4306829859 cites W2986472428 @default.
• W4306829859 cites W3002604830 @default.
• W4306829859 cites W3004921365 @default.
• W4306829859 cites W3037349914 @default.
• W4306829859 cites W34571862 @default.
• W4306829859 cites W4293241248 @default.
• W4306829859 doi "https://doi.org/10.1200/jco.22.00164" @default.
• W4306829859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36260832" @default.
• W4306829859 hasPublicationYear "2023" @default.
• W4306829859 type Work @default.
• W4306829859 citedByCount "29" @default.
• W4306829859 countsByYear W43068298592022 @default.
• W4306829859 countsByYear W43068298592023 @default.
• W4306829859 crossrefType "journal-article" @default.
• W4306829859 hasAuthorship W4306829859A5001497458 @default.
• W4306829859 hasAuthorship W4306829859A5002485541 @default.
• W4306829859 hasAuthorship W4306829859A5022827643 @default.
• W4306829859 hasAuthorship W4306829859A5025967381 @default.
• W4306829859 hasAuthorship W4306829859A5027150108 @default.
• W4306829859 hasAuthorship W4306829859A5027798049 @default.
• W4306829859 hasAuthorship W4306829859A5029952866 @default.
• W4306829859 hasAuthorship W4306829859A5031842995 @default.

• next